Home
Companies
Catalysts
Deep Dives
Tepezza
teprotumumab
APPROVED
Drug Profile
Modality
Antibody
Route
IV
Therapy Area
Rare Disease
Launch
2020-01-21
US LOE
2032-01-21
Peak Sales Est
$2700M
Formulations
[{"id":"tepezza-iv","route":"IV","setting":"INFUSION_CENTER","frequency":"Every 3 weeks x8","is_prim
Companies
AMGN
(LICENSEE)
0%
GMAB
(ROYALTY)
0%
Mechanism: IGF-1R inhibitor
Expert:
Monoclonal antibody inhibiting insulin-like growth factor 1 receptor, reducing orbital fibroblast activation in thyroid eye disease.
Everyday:
Blocks a growth factor receptor to reduce inflammation and tissue swelling.
Targets: ["IGF-1R"]
Revenue History
Period
Revenue ($M)
2025
$1,903M
Q4 2024
$460M
Q4 2025
$457M
2024
$1,900M
Programs (1)
Indication
Stage
Key Study
Regional Status
TED
APPROVED
OPTIC
[{"stage":"APPROVED","region":"US","approval_date":"2020-01-21"}]
Notes
First and only approved treatment for thyroid eye disease (TED). Acquired by Amgen via Horizon. Genmab receives royalties. High-priced specialty drug.
Data from Supabase · Updated 2026-03-24